$KRRO
Korro Bio, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020012977 Filed on March 26, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019
Revenue $7.264M $4.709M $28.95M
YoY Change
Cost Of Revenue $0.00 $16.00M
YoY Change
Gross Profit $4.710M $12.95M
YoY Change
Gross Profit Margin 100.02% 44.74%
Selling, General & Admin $6.250M $5.000M $14.84M
YoY Change 153.04% 108.33% 110.2%
% of Gross Profit 106.16% 114.59%
Research & Development $6.670M $6.200M $18.78M
YoY Change 93.33% 112.33% 58.11%
% of Gross Profit 131.63% 145.05%
Depreciation & Amortization $215.0K $220.0K $813.0K
YoY Change 28.74% 4.76% 24.31%
% of Gross Profit 4.67% 6.28%
Operating Expenses $12.92M $11.20M $49.62M
YoY Change 118.23% 110.53% 161.94%
Operating Profit -$5.655M -$6.490M -$20.68M
YoY Change 9.14%
Interest Expense $780.0K $1.000M $1.930M
YoY Change 766.67% 566.67% 3760.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.875M -$5.490M -$18.75M
YoY Change -16.32% 0.73% -2.21%
Income Tax $38.00K $0.00
% Of Pretax Income
Net Earnings -$4.913M -$5.493M -$18.75M
YoY Change -15.67% 0.84% -2.2%
Net Earnings / Revenue -67.63% -116.65% -64.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$159.1K -$176.2K -$601.9K
COMMON SHARES
Basic Shares Outstanding 30.95M 30.78M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.1M $217.4M $217.4M
YoY Change 415.17%
Cash & Equivalents $204.9M $200.2M $200.2M
Short-Term Investments $3.000M $17.20M $17.20M
Other Short-Term Assets $597.0K $199.0K $3.200M
YoY Change 25.16% 433.33%
Inventory
Prepaid Expenses
Receivables $200.0K $800.0K $800.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $209.9M $221.4M $221.4M
YoY Change 415.53% 416.08%
LONG-TERM ASSETS
Property, Plant & Equipment $4.000M $1.762M $1.800M
YoY Change 16.61% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $101.0K $100.0K
YoY Change 1.0% 0.0%
Total Long-Term Assets $5.800M $1.863M $1.800M
YoY Change 15.64% 12.5%
TOTAL ASSETS
Total Short-Term Assets $209.9M $221.4M $221.4M
Total Long-Term Assets $5.800M $1.863M $1.800M
Total Assets $215.7M $223.2M $223.2M
YoY Change 401.07% 401.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $1.219M $1.200M
YoY Change -34.57% -36.84%
Accrued Expenses $2.400M $3.239M $3.200M
YoY Change 85.19% 88.24%
Deferred Revenue $48.15M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.70M $52.78M $52.80M
YoY Change 1289.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $180.0K $0.00
YoY Change -48.42%
Other Long-Term Liabilities $7.100M $3.100M $3.100M
YoY Change 933.33%
Total Long-Term Liabilities $7.100M $180.0K $3.100M
YoY Change -48.42% 933.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.70M $52.78M $52.80M
Total Long-Term Liabilities $7.100M $180.0K $3.100M
Total Liabilities $50.90M $55.86M $55.90M
YoY Change 607.59%
SHAREHOLDERS EQUITY
Retained Earnings -$68.89M
YoY Change 40.34%
Common Stock $236.2M
YoY Change 29204.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $164.8M $167.4M $167.4M
YoY Change
Total Liabilities & Shareholders Equity $215.7M $223.2M $223.2M
YoY Change 401.07% 401.57%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$4.913M -$5.493M -$18.75M
YoY Change -15.67% 0.84% -2.2%
Depreciation, Depletion And Amortization $215.0K $220.0K $813.0K
YoY Change 28.74% 4.76% 24.31%
Cash From Operating Activities -$9.363M -$29.74M $34.22M
YoY Change 52.24% 531.42% -300.99%
INVESTING ACTIVITIES
Capital Expenditures $343.0K -$420.0K $1.064M
YoY Change -25.27% 75.0% 144.04%
Acquisitions
YoY Change
Other Investing Activities $14.03M $5.850M -$17.20M
YoY Change -140.22%
Cash From Investing Activities $13.69M $5.430M -$18.26M
YoY Change -138.73% -2362.5% 4088.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $309.0K $80.06M
YoY Change 306.58% 109573.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 309.0K 82.20M 142.0M
YoY Change -9.65% 135.73% 240.47%
NET CHANGE
Cash From Operating Activities -9.363M -29.74M 34.22M
Cash From Investing Activities 13.69M 5.430M -18.26M
Cash From Financing Activities 309.0K 82.20M 142.0M
Net Change In Cash 4.634M 57.89M 158.0M
YoY Change -111.26% 93.48% 551.37%
FREE CASH FLOW
Cash From Operating Activities -$9.363M -$29.74M $34.22M
Capital Expenditures $343.0K -$420.0K $1.064M
Free Cash Flow -$9.706M -$29.32M $33.15M
YoY Change 46.86% 555.93% -289.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Entity Registrant Name
EntityRegistrantName
Frequency Therapeutics, Inc.
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200158000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
17197000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4000000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
748000
CY2019 dei Local Phone Number
LocalPhoneNumber
389-1970
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei City Area Code
CityAreaCode
866
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001703647
CY2019 dei Entity File Number
EntityFileNumber
001-39062
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2324450
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
19 Presidential Way
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Woburn
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01801
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2019 dei Trading Symbol
TradingSymbol
FREQ
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 us-gaap Assets
Assets
44548000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1863000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
161000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2900000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
54000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49088000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-48282000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44548000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1749000
CY2019Q2 dei Entity Public Float
EntityPublicFloat
0
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30946354
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42189000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
42937000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1511000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-18746000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
54000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
221355000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1762000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
101000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
349000
CY2018Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
3773000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
236161000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
804000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
165000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30844507
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2084710
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30844507
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2084710
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28947000
CY2019 us-gaap Royalty Expense
RoyaltyExpense
16000000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18784000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11880000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11966000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14838000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7064000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4340000
CY2019 us-gaap Operating Expenses
OperatingExpenses
49622000
CY2018 us-gaap Operating Expenses
OperatingExpenses
18944000
CY2017 us-gaap Operating Expenses
OperatingExpenses
16306000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-20675000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-18944000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-16306000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1784000
CY2018 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-106000
CY2017 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-174000
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-269000
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3749000
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
138000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
151000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-19168000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-20237000
CY2019 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1054000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19800000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19168000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20237000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.29
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.53
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-28.79
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8649245
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1530218
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
702918
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
54000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-9663000
CY2017 freq Stock Issued During Period Value Issued For Patent License
StockIssuedDuringPeriodValueIssuedForPatentLicense
140000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-29642000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
54000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18692000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19168000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20237000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
455000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
73000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80062000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3609000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
366000
CY2019 freq Convertible Preferred Stock Accretion Of Dividend
ConvertiblePreferredStockAccretionOfDividend
1054000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
79696000
CY2019 freq Stock Issued During Period Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering
StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering
151715000
CY2019 us-gaap Profit Loss
ProfitLoss
-18746000
CY2018 us-gaap Profit Loss
ProfitLoss
-19168000
CY2017 us-gaap Profit Loss
ProfitLoss
-20237000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3609000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
455000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
91000
CY2019 us-gaap Depreciation
Depreciation
813000
CY2018 us-gaap Depreciation
Depreciation
654000
CY2017 us-gaap Depreciation
Depreciation
531000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
106000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
174000
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
54000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
140000
CY2019 freq Deferred Lease Incentives
DeferredLeaseIncentives
160000
CY2018 freq Deferred Lease Incentives
DeferredLeaseIncentives
159000
CY2017 freq Deferred Lease Incentives
DeferredLeaseIncentives
-662000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3253000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
727000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-142000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-644000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
869000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-231000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
51052000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1490000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
677000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
365000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34215000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17024000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14614000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1064000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
436000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1863000
CY2019 freq Payment For Proceeds From Sale Of Available For Sale Securities Debt
PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt
282618000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
265421000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18261000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-436000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1863000
CY2018 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
3773000
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5000000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
73000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
142015000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41712000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27978000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
157969000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24252000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11501000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42189000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17937000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6436000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18606359
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10906692
CY2019 freq Non Cash Dividend On Cumulative Convertible Preferred Stock
NonCashDividendOnCumulativeConvertiblePreferredStock
1054000
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
151715000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
200158000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
94000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
5375000
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
18743000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
149
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.05
CY2019 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-11-30
CY2019Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.148467
CY2019 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.7355
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
148724922
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19554414
CY2019Q4 freq Prepaid Rent And Deposits Current
PrepaidRentAndDepositsCurrent
63000
CY2019Q4 freq Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
801000
CY2018Q4 freq Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
428000
CY2019Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
805000
CY2018Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
161000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2132000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
199000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
159000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3828000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2764000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2066000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1253000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2686000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1034000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
435000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
322000
CY2019Q4 freq Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
118000
CY2018Q4 freq Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
393000
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
114208722
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7828326
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19288847
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10915817
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.794
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.811
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.790
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
357170
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
126253
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5896
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.041
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2990
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
244
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13820000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
717000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2018 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16204000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12229000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.130
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.028
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.004
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.050
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.018
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.029
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.036
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.020
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.230
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.263
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.259
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13253000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10710000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1138000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1014000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
358000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
256000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
686000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
68000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
48000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
22000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
496000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
189000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
210000
CY2019Q4 freq Deferred Tax Assets Liabilities Property Plant And Equipment
DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
36000
CY2018Q4 freq Deferred Tax Assets Liabilities Property Plant And Equipment
DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
-51000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16204000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12229000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017Q4 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0
CY2019 freq Operating Loss Deduction Limitation As Percentage Of Taxable Income
OperatingLossDeductionLimitationAsPercentageOfTaxableIncome
0.80
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
269000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
271000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
504000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3613000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4741000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4883000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5034000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
35596000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
54371000
CY2019 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
705000
CY2019 freq Operating Leases Term Of Contract
OperatingLeasesTermOfContract
P5Y
CY2019 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2018 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2017 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1.00
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2019 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
1.00
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24238000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4709000
CY2019Q1 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
5826000
CY2019Q2 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
6852000
CY2019Q3 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
24813000
CY2019Q4 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
10202000
CY2019 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
47693000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5826000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6852000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-575000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-5493000
CY2019Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1014000
CY2019Q4 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
40000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5826000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6852000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1589000
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5533000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.24
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.42
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2018Q1 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
4149000
CY2018Q2 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
4436000
CY2018Q3 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
5136000
CY2018Q4 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
5447000
CY2018 freq Operating And Non Operating Expenses Net
OperatingAndNonOperatingExpensesNet
19168000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4149000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-4436000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-5136000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-5447000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4149000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4436000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5136000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5447000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.03
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.01
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.26
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.23

Files In Submission

Name View Source Status
0001564590-20-012977-index-headers.html Edgar Link pending
0001564590-20-012977-index.html Edgar Link pending
0001564590-20-012977.txt Edgar Link pending
0001564590-20-012977-xbrl.zip Edgar Link pending
exhibit10_51.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
freq-10k_20191231.htm Edgar Link pending
freq-20191231.xml Edgar Link completed
freq-20191231.xsd Edgar Link pending
freq-20191231_cal.xml Edgar Link unprocessable
freq-20191231_def.xml Edgar Link unprocessable
freq-20191231_lab.xml Edgar Link unprocessable
freq-20191231_pre.xml Edgar Link unprocessable
freq-ex1013_758.htm Edgar Link pending
freq-ex211_757.htm Edgar Link pending
freq-ex231_1116.htm Edgar Link pending
freq-ex311_9.htm Edgar Link pending
freq-ex312_8.htm Edgar Link pending
freq-ex321_7.htm Edgar Link pending
freq-ex322_6.htm Edgar Link pending
freq-ex43_875.htm Edgar Link pending
g5lvsimk4gaq000001.jpg Edgar Link pending
g5lvsimk4gaq000002.jpg Edgar Link pending
g5lvsimk4gaq000003.jpg Edgar Link pending
g5lvsimk4gaq000004.jpg Edgar Link pending
g5lvsimk4gaq000005.jpg Edgar Link pending
g5lvsimk4gaq000006.jpg Edgar Link pending
g5lvsimk4gaq000007.jpg Edgar Link pending
g5lvsimk4gaq000008.jpg Edgar Link pending
g5lvsimk4gaq000009.jpg Edgar Link pending
g5lvsimk4gaq000010.jpg Edgar Link pending
g5lvsimk4gaq000011.jpg Edgar Link pending
g5lvsimk4gaq000012.jpg Edgar Link pending
g5lvsimk4gaq000013.jpg Edgar Link pending
g5lvsimk4gaq000014.jpg Edgar Link pending
g833164bawa43.gif Edgar Link pending
g833164dsp1.jpg Edgar Link pending
g833164page0035.jpg Edgar Link pending
g833164page036.jpg Edgar Link pending
g833164page045.jpg Edgar Link pending
g833164page06.jpg Edgar Link pending
g833164page46.jpg Edgar Link pending
g833164page46a.jpg Edgar Link pending
g833164pagebb.jpg Edgar Link pending
gqr1p20dfppl000001.jpg Edgar Link pending
gqr1p20dfppl000002.jpg Edgar Link pending
gqr1p20dfppl000003.jpg Edgar Link pending
gqr1p20dfppl000004.jpg Edgar Link pending
gqr1p20dfppl000005.jpg Edgar Link pending
gqr1p20dfppl000006.jpg Edgar Link pending
gqr1p20dfppl000007.jpg Edgar Link pending
gqr1p20dfppl000008.jpg Edgar Link pending
gqr1p20dfppl000009.jpg Edgar Link pending
gqr1p20dfppl000010.jpg Edgar Link pending
gqr1p20dfppl000011.jpg Edgar Link pending
gqr1p20dfppl000012.jpg Edgar Link pending
gqr1p20dfppl000013.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending